Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1281827 | 0.88 | USP2 (0.39) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL2473154 | 0.87 | MEN1 (0.39) | USP2SMN1; SMN2CYP4F2CYP4A11MEN1 | |
| SCHEMBL10112411 | 0.87 | CYP4F2 (0.39) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL2604311 | 0.86 | PKM (0.47) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL963907 | 0.86 | USP2 (0.47) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL550116 | 0.85 | KMT2A (0.46) | MEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL7309006 | 0.85 | USP2 (0.43) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL20565162 | 0.84 | USP2 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL390461 | 0.84 | USP2 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11PKM | |
| SCHEMBL606159 | 0.84 | USP2 (0.42) | USP2SMN1; SMN2CYP4F2CYP4A11PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4570320-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025104411-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2025-05-22 | — | — | WO | disclosed |
| EP-4069237-B1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2011143148-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143148-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| CN-102239168-A | Substituted piperidine spiro pyrrolidinone and piperidinones used as h3 modulators | SANOFI AVENTIS | 2011-11-09 | — | — | CN | disclosed |
| US-20110257213-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110257213-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110257213-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-20 | — | — | US | disclosed |
| EP-2373652-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS | SANOFI (FR) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010065803-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065803-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
| US-20070129345-A1 | Lactam compounds and methods of using the same | INCYTE CORPORATION | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | USP2 4420/4885SMN1; SMN2 2648/4885CYP4F2 4036/4885 |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | USP2 374/4885SMN1; SMN2 4306/4885CYP4F2 3520/4885 |
| US-20070129345-A1 | Lactam compounds and methods of using the same | HSD11B1, HSD17B11, HSD17B1 | USP2 1990/4885SMN1; SMN2 2604/4885CYP4F2 209/4885 |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | ITGB6, ITGA6, ITGAV | USP2 4326/4885SMN1; SMN2 2499/4885CYP4F2 4311/4885 |
| US-20110257213-A1 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HRH4, PRLHR | USP2 4530/4885SMN1; SMN2 1653/4885CYP4F2 1534/4885 |
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, BCL9, BCL9L | USP2 43/4885SMN1; SMN2 3067/4885CYP4F2 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.